Epidemiologic and mucosal immunologic aspects of HPV infection and HPV-related cervical neoplasia in the lower female genital tract: A review

International Journal of Gynecological Cancer

Volumn 11, Issue 1, 2001, Pages 9-17

  Tjiong, M Y ^a   Out, T A ^a   Ter Schegget, J ^a   Burger, M P M ^b   Van Der Vange, N ^c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b CENTRAL LABORATORY   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Cervical neoplasia; HPV; Mucosal immunology

Indexed keywords

VACCINE;

CONDYLOMA; DEVELOPING COUNTRY; GENITAL SYSTEM; HUMORAL IMMUNITY; IMMUNE RESPONSE; LYMPHOID TISSUE; PATHOGENESIS; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SEXUALLY TRANSMITTED DISEASE; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS INFECTION; VIRUS TRANSMISSION; WART VIRUS;

DEVELOPING COUNTRIES; DISEASE TRANSMISSION; FEMALE; HUMANS; INCIDENCE; MUCOUS MEMBRANE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; TUMOR VIRUS INFECTIONS; UROGENITAL SYSTEM; UTERINE CERVICAL NEOPLASMS; VIRAL VACCINES;

EID: 0035100549     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.2001.011001009.x     Document Type: Review

References (118)

1. Estimates of the worldwide incidence of eighteen major cancers in 1985
2. Cancer statistics
3. Duration of preclinical cervical cancer and reduction in incidence of invasive cancer following negative pap smears
4. Risk factors for cervical cancer by histology
5. Venereal factors in human cervical cancer: Evidence from marital clusters
6. Risk factors for cervical intraepithelial neoplasia
7. A comparison review of key epidemiological studies in cervical cancer related to current searches for transmissible agents
8. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia
9. Sexual behaviour and papillomavirus exposure in cervical intraepithelial neoplasia: A population-based case-control study
10. Cigarette smoking and human papillomavirus in patients with reported cervical cytological abnormality
11. Malignant transformation of human ectocervical cells immortalized by HPV 18: In vitro model of carcinogenesis by cigarette smoke
12. Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papillomavirus infection
13. Risk factors for cervical cancer in Colombia and Spain
14. Parity as a risk factor for cervical cancer
15. Sexually transmitted agents and cervical neoplasia in Colombia and Spain
16. Oral contraceptive use and adenocarcinoma of cervix
17. Clear cell adenocarcinoma of the lower genital tract. Correlation of mother's recall of diethylstilbestrol history with obstetrical records
18. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group
19. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer
20. Papillomavirus infections - A major cause of human cancers
21. Human papillomavirus infection of the cervix: Relative risk associations of 15 common anogenital types
22. Human papillomaviruses
23. Papovaviridae: Capsid structure and capsid protein function
24. Interaction of papillomaviruses with the cell surface
25. E1 protein of human papillomavirus is a DNA helicase/ATPase
26. Viral E1 and E2 proteins support replication of homologous and heterologous papillomaviral origins
27. Study of the E2 gene product of the cottontail rabbit papillomavirus reveals a common mechanism of transactivation among papillomaviruses
28. The carboxyterminal domain shared by the bovine papillomavirus E2 transactivator and repressor proteins contains a specific DNA binding activity
29. Transcriptional regulation of the human papillomavirus-16, E6-E7 promoter by a keratinocyte-dependent enhancer, and by viral E2 trans-activator and repressor gene products: Implications for cervical carcinogenesis
30. Mechanism of action of the papillomavirus E2 repressor: Repression in the absence of DNA binding
31. Specific interaction between HPV-16 E1-E4 and cytokeratins results in collapse of the epithelial cell intermediate filament network
32. Papillomaviruses causing cancer: Evasion from host-cell control in early events in carcinogenesis
33. Regulation of the cell cycle by viral oncoproteins
34. Association of human papillomavirus types 16 and 18, E6 proteins with p53
35. The human papilloma virus-16, E7 oncoprotein is able to bind to the retinoblastoma gene product
36. Human papillomavirus type 16, E7 regulates E2F and contributes to mitogenic signalling
37. Aetiology, pathogenesis, and pathology of cervical neoplasia
38. A brief synopsis of the role of human papillomaviruses in cervical carcinogenesis
39. Human papillomavirus type 16 and 18 gene expression in cervical neoplasias
40. Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells
41. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells
42. The major human papillomavirus protein in cervical cancers is a cytoplasmic phosphoprotein
43. Identification of the HPV-16 E6 protein from transformed mouse cells and human cervical carcinoma cell lines
44. Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines
45. Identification of human papillomavirus type 18, E6 polypeptide in cells derived from human cervical carcinomas
46. Different human cervical carcinoma cell lines show similar transcription patterns of human papillomavirus type 18 early genes
47. Transcription of human papillomavirus type 16 early genes in a cervical cancer and a cancer-derived cell line and identification of the E7 protein
48. Identification of the human papillomavirus type 18, E6 and E6 proteins in nuclear protein fractions from human cervical carcinoma cells grown in the nude mouse or in vitro
49. Sexual behavior and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young women
50. Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is age-dependent
51. Transience of cervical HPV infection in sexually active, young women with normal cervicovaginal cytology
52. Human papillomavirus infection is transient in young women: A population-based cohort study
53. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women
54. Natural history of cervicovaginal papillomavirus infection in young women
55. The invasive potential of carcinoma in situ of the cervix
56. Epidemiological evidence for age-dependent regression of pre-invasive cervical cancer
57. Cervical dysplasia in HIV-seropositive women: Role of human papillomavirus infection and immune status
58. Human papillomavirus infection and cervical intraepithelial neoplasia in women with renal allografts
59. Human papillomavirus infection in women infected with the human immunodeficiency virus
60. Anal and cervical human papillomavirus infection and risk of anal and cervical epithelial abnormalities in human immunodeficiency virus-infected women
61. The increased frequency of cervical dysplasia-neoplasia in women infected with the human immunodeficiency virus is related to the degree of immuno-suppression
62. Cervical cytologic abnormalities and papillomavirus in women infected with human immunodeficiency virus
63. High frequency of latent and clinical human papillomavirus cervical infections in immunocompromised human immunodeficiency virus-infected women
64. Prevalence, risk factors, and accuracy of cytologic screening for cervical intraepithelial neoplasia in women with the human immunodeficiency virus
65. Human papillomavirus and lower genital neoplasia in renal transplant patients
66. Gynecologic malignancies in immunosuppressed organ homograft recipients
67. Overview of the mucosal immune system
68. Regional specialization in the mucosal immune system: What happens in the microcompartments?
69. Mucosal immunoglobulins and their contribution to defence mechanisms: An overview
70. Mucosal immunity to vaccines: Current concepts for vaccine development and immune response analysis
71. Molecular and cellular aspects of the secretory immunoglobulin system
72. Ontogeny of the mucosal immune system and IgA deficiency
73. Mucosal immunity and vaccination
74. Secretory immune system of the female reproductive tract II. Local immune system in normal and infected fallopian tube
75. Colonization in the rectum and uterine cervix with group B streptococci may induce specific antibody responses in cervical secretions of pregnant women
76. Mucosal immunity in the female genital tract
77. Normal uterine cervix: Characterization of isolated lymphocyte phenotypes and immunoglobulin secretion
78. Mucosal immunity to human papillomavirus in the female reproductive tract
79. Langerhans' cells and lymphocyte subsets in the female genital tract
80. Immunoglobulin levels and antibody to Candida Albicans in human cervicovaginal secretions
81. Systemic and secretory humoral immunity in the normal human vaginal tract
82. Comparative analysis of methods for collection and measurement of immunoglobulins in cervical and vaginal secretions of women
83. Mucosal immune system of the human genital tract
84. Secretory immunity in the female reproductive tract
85. B cell activation and antibody production
86. Subpopulations of Langerhans' cells in cervical neoplasia
87. Quantitative assessment of Langerhans' cells in human cervical intraepithelial neoplasia and wart virus infection
88. Expression of major histocompatibility class II antigens by Langerhans' cells in cervical intraepithelial neoplasia
89. Langerhans cells and epithelial cell modifications in cervical intraepithelial neoplasia: Correlation with human papillomavirus infection
90. Dendritic cells: Unique leukocyte populations which control the primary immune response
91. Analysis of human genital warts (condylomata acuminata) and other genital tumors for human papillomavirus type 6 DNA
92. Partial characterization of viral DNA from human genital warts (Condylomata acuminata)
93. Physical characterization of deoxyribonucleic acids of different human papilloma viruses (HPV)
94. Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes
95. Assembled baculovirus-expressed human papillomavirus type 11, L1 capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titres of neutralizing antibodies
96. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies
97. Serological differentiation of human papillomavirus types 11, 16 and 18 using recombinant virus-like particles
98. Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera
99. Serological immune response to HPV
100. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic
101. Efficient self-assembly of human papillomavirus type 16, L1 and L1-L2 into virus-like particles
102. Detection of antibodies against human papillomavirus (HPV) type 16 virions by enzyme-linked immunosorbent assay using recombinant HPV 16, L1 capsids produced by recombinant baculovirus
103. Self-assembly of human papillomavirus type 16 capsids by expression of the L1 protein in insect cells
104. Immunologic responses to human papillomavirus infection
105. Comparison of peptide enzyme-linked immunosorbant assay and radioimmunoprecipitation assay with in vitro-translated proteins for detection of serum antibodies to human papillomavirus type 16, E6 and E7 proteins
106. Antibodies against linear and conformational epitopes of the human papillomavirus (HPV) type 16, E6 and E7 oncoproteins in sera of cervical cancer patients
107. The association of human papillomavirus type 16, E6 and E7 antibodies with stage of cervical cancer
108. Antibodies against early proteins of human papillomaviruses as diagnostic markers for invasive cervical cancer
109. Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in cervical carcinoma patients from Russia
110. Cervical mucus antibodies against human papillomavirus type 16, 18, and 33 capsids in relation to presence of viral DNA
111. Detection of IgA antibodies against human papillomavirus in cervical secretions from patients with cervical intraepithelial neoplasia
112. Antibodies against papillomavirus antigens in cervical secretions from condyloma patients
113. Seric and local antibodies against a synthetic peptide of HPV16
114. Human papillomavirus DNA and anti-HPV secretory IgA antibodies in cytologically normal cervical specimens
115. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16
116. Detection of cervical antibodies to human papillomavirus type 16 (HPV-16) antigens in relation to detection of HPV-16 DNA and cervical lesions
117. IgG antibodies against human papillomavirus type 16, E7 proteins in cervicovaginal washing fluid from patients with cervical neoplasia